Diabetes of the exocrine pancreas (DEP) is a form of diabetes that occurs due to pancreatic disease. It is far more common than has been previously considered, with a recent study showing 1.8% of adults with new-onset diabetes should have been classified as DEP. The majority is misdiagnosed as type 2 diabetes mellitus (T2DM). Patients with DEP exhibit varying degrees of exocrine and endocrine dysfunction. Damage to the islet of Langerhans effects the secretion of hormones from the β, α, and pancreatic polypeptide cells; the combination of low insulin, glucagon, and pancreatic polypeptide contributes to rapid fluctuations in glucose levels. This form of "brittle diabetes" may result in the poorer glycemic control observed in patients with DEP, when compared with those with T2DM. Diabetes of the exocrine pancreas has a different natural history to other forms of diabetes; patients are more likely to require early insulin initiation compared with those with T2DM. Therefore, individuals with DEP should be advised about the symptoms of decompensated hyperglycemia, although they are less likely to develop ketoacidosis. Clinicians should screen for DEP in patients with acute or chronic pancreatitis, following pancreatic resection, or with co-existing cystic fibrosis or hemochromatosis. Incident diabetes may herald the onset of pancreatic ductal carcinoma in a small subset of patients. Once identified, patients with DEP can benefit from specific lifestyle advice, pancreatic enzyme replacement therapy, metformin treatment, appropriate insulin dosing, and monitoring. Further research is needed to establish the ideal treatment regimens to provide optimal clinical outcomes for this unique form of diabetes.
Introduction
Diabetes of the exocrine pancreas (DEP) is a form of diabetes that occurs when the pancreas is damaged or destroyed. 1 It is synonymous with secondary pancreatic diabetes and type 3c diabetes, a term that has been challenged as less useful. 2 This form of diabetes, as with other sub-classifications, is heterogeneous and encompasses a number of distinct conditions. DEP is characterized by varying degrees of both exocrine and endocrine dysfunction. While the insulin-secreting β cells of the islets represent approximately 70% of the hormone-secreting cells, the α, δ, and pancreatic polypeptide (PP) cells that secrete glucagon, somatostatin, and PP, respectively, are also affected (Fig. 1) . The loss of these other islet cell hormones impacts on the clinical presentation, pathophysiology, and course of DEP.
Epidemiology
Studies suggest that DEP is underdiagnosed and usually mistaken for type 2 diabetes mellitus (T2DM). 3 As the clinical course is different to type 1 diabetes mellitus (T1DM) or T2DM, only with the correct diagnosis can optimal treatment and follow-up be provided. 4 There has been a paucity of epidemiological data on the community incidence of DEP. Recently, data from the UK Royal College of General Practitioners Research and Surveillance Centre collected from 2005 to 2016 were used to determine the incidence of prior pancreatic disease in the 31 789 cases of adults newly diagnosed with diabetes. In this retrospective analysis, 559 cases of diabetes following pancreatic disease were identified with a median follow-up time of 4.5 years from the date of pancreatic diagnosis. Of these patients, 87.8% had been classified by clinicians as T2DM; 7.7% as T1DM; and only 2.7% correctly as DEP. Surprisingly, when reclassified, the proportion of adults with DEP (1.8%) was higher than the proportion with T1DM (1.1%). 4 The prevalence of DEP may be even higher in a hospital setting. A retrospective study of 1868 inpatients with diabetes demonstrated that 9.2% had DEP, defined using stringent criteria requiring the presence of pathological pancreatic imaging and evidence of exocrine dysfunction. 3 Similar to the previous community study, half of the patients with DEP were initially misclassified as T2DM.
surgical pancreatic resection, pancreatic cancer, hemochromatosis, and congenital agenesis of the pancreas (Table 1) . Acute pancreatitis (AP), relapsing pancreatitis, and chronic pancreatitis (CP) (of any etiology) result in a progressive inflammatory process, fibrosis, and sclerosis of the endocrine tissue, reducing both the number of islets and their functional capacity.
The risk factors and causes of pancreatitis are diverse and multifactorial. While clinically, alcohol is the most attributed precipitant of recurrent AP and CP, gallstones is the most common cause of AP. Other risk factors include metabolic, environmental, and genetic factors. 6 It is increasingly apparent that mutations in genes involved in trypsinogen activation and intra-pancreatic trypsin regulation increase the risk of pancreatitis. 7 Trypsin activity, rather than its pro-enzyme, or zymogen, trypsinogen, causes autolysis and auto-digestion of pancreatic tissue; this triggers an immune response and inflammation that may result in an episode of pancreatitis.
The most common genetic susceptibility genes associated with pancreatitis and DEP are listed and briefly discussed in Table 2 . Variants of these genes increase not only the risk of an individual developing pancreatitis but also the risk of DEP. Individuals with CP may carry more than one mutation in these disease-associated genes, 12 and new polymorphisms, complex gene-gene interactions, and gene-environmental interactions continue to be discovered. 8 The interaction of environmental and metabolic risk factors with these susceptibility genes is apparent from the wide individual risk of developing CP from ethanol consumption; 13 idiosyncratic drug reactions; and hypercalcemia and hypertriglyceridemia. 7 The other causes of DEP, not necessarily related to pancreatitis, are listed in Table 3 . DEP associated with pancreatic neoplasms is common (68% in one study) and often occurs before the onocological diagnosis of adenocarcinoma of the pancreas. 26 This form of DEP is not thought to be a consequence of islet loss; diabetogenic factors secreted by the pancreatic tumor may reduce insulin secretion and sensitivity. 5 Consistent with other paraneoplastic manifestations of disease, surgical or oncological treatment of the tumor can restore glucose homeostasis.
Total pancreatectomy inevitably results in diabetes because of the removal of islet cells. Partial resections (depending on the type and extent) may also result in DEP, particularly if there is a compromised β cell reserve or progression of an underlying disease such as CP. 27 Indeed, the incidence of diabetes after a distal pancreatectomy is higher when performed for CP, compared with operations performed for pancreatic tumors (5-10%) where the remaining β cells may be intact.
The overall prevalence of DEP is increasing, with one study showing that it has nearly tripled over the last decade. 28 DEP is likely to continue to become a more prominent condition with the increasing rates of CP, pancreatectomy, and longer survival of patients with cystic fibrosis (CF).
Pathophysiology
In contrast to the isolated autoimmune destruction of the β cell that occurs in T1DM (low insulin level) and the insulin resistance states (acanthosis nigricans and high insulin level) associated with T2DM, DEP affects all cell subtypes within the islets of Langerhans (Table 4) . This results in a complete islet hormone deficiency (low insulin, glucagon, and PP levels) with a number of clinically relevant effects.
The loss of β cells mass and insulin secretory capacity leads to insulin deficiency and consequent hyperglycemia (reduced glucose utilization, increased hepatic gluconeogenesis, and glycogen breakdown). 29, 30 Glucagon secretion from pancreatic α Diabetes of the exocrine pancreas K Wynne et al. Post-pancreatectomy diabetes The extent and location of surgical resection contribute to the risk of pancreatic diabetes. Deficiencies of endocrine rather than exocrine function are more susceptible to pancreatic resection. While insulin-secreting β cells are distributed throughout the pancreas, the α and δ, and PP cells are selectively found in the tail and head of the pancreas (respectively). The development of pancreatic diabetes after distal pancreatectomy is around 20% but more in obese patients and up to 85% in patients with prior chronic pancreatitis. Following a pancreaticoduodenectomy, new onset diabetes at a year is around 17% rising more than 50% with long-term follow up or if atrophy of the remnant distal pancreas occurs.
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Hemochromatosis Hemochromatosis is due to iron overload in the body from any cause. The liver, heart, joints, and endocrine organs are most likely to be affected. Diabetes occurs due to iron overload in the pancreatic islets and is characterized by both insulin deficiency and in hepatic insulin resistance. Hereditary hemochromatosis (HHC) and transfusion-related iron overload are the commonest causes of hemochromatosis. HHC is one of the commonest autosomal recessive conditions seen in northern European. Two mutations in the human hemochromatosis protein gene that leads to unregulated absorption of iron from the gut have been described. Cys282Ty homozygosity or compound heterozygosity C282Y/H63D is found in most patients with HHC. The prevalence of homozygous Cys282Tyr mutations in populations of Northern European ancestry is 0.3-0.7% and 9-14% for heterozygous mutations.
Powell et al. 23 Milla et al. 24 Schneider et al. Pancreatic polypeptide, secreted from PP cells in the ventral pancreas in response to a mixed nutrient meal, potentiates the effect of insulin on hepatic glucose metabolism. A loss of PP results in hepatic insulin resistance 33 due to a reduction in the availability of hepatic insulin receptors. 31 In the context of insufficient insulin secretion, this contributes to hyperglycemia and diabetes. Notably, PP administration has been shown to improve glucose homeostasis and conservative surgical procedures that preserve the head of the pancreas appear to reduce the incidence of postoperative diabetes. 33 The release of incretin hormones may be disordered in DEP, leading to a suboptimal post-prandial insulin secretion. In normal physiology, fatty acids and other nutrients cause the release of glucagon-like peptide-1 (GLP-1) from intestinal L cells in the ileum and large intestine and glucose-dependent insulinotropic polypeptide from K cells of the small intestine. A loss of pancreatic exocrine function, and consequently fat hydrolysis, can result in loss of the incretin response, impaired insulin release, and dysglycemia. 3, 34, 35 Adipokines are elevated during episodes of AP and are positively associated with the development of insulin resistance and chronic hyperglycemia. 36 Inflammatory mediators may also contribute to insulin resistance and hyperglycemia during acute exacerbations of CF. 37 The pro-inflammatory cytokines (interleukin 1β, tumor necrosis factor α, and interferon γ) reduce glucose-stimulated insulin release. 5 Inflammation also increases the expression of adrenomedullin and vanin-1, and these factors may have a role in DEP due to CP and pancreatic ductal adenocarcinoma. 5 Hyperglycemia caused by ductal adenocarcinoma has a distinctive pathophysiology; evolving evidence has demonstrated paraneoplastic factors that cause insulin resistance and β cell dysfunction. Early studies suggested raised levels of plasma islet amyloid polypeptide contributed to insulin resistance, but subsequent studies have not supported this role. Adrenomedullin, which is over expressed in pancreatic ductal adenocarcinoma, has been identified as an inhibitor of insulin secretion and also promotes invasive tumor behavior. 5 
Screening
Patients with a past history of pancreatitis should be screened for endocrine and exocrine insufficiency. 4 Consensus guidelines advocate (at minimum) annual fasting glucose and hemoglobin A1c (HbA1c). 38 In the hospital-based study by Ewald et al. described previously, the majority (80%) of patients with DEP had underlying CP, with pancreatic cancer (8%) being the second most frequent diagnosis. 3 A study of 500 consecutive patients with CP found DEP had developed in over 80% patients in the 25 years after diagnosis. 39 Similarly, a study of 2011 patients found that 28% patients had developed DEP after 10 years and 90% after 50 years of CP. 40 Acute pancreatitis should not be underestimated as a precipitant of DEP, especially as there is a higher background prevalence of AP than any other pancreatic disease. In the large epidemiological study by Woodmansey et al. described previously, AP was the most common pancreatic disease preceding diabetes. 4 There was a high proportion of AP (61%) causing DEP in a study of the New Zealand population, which demonstrated an overall prevalence of 1.13 per 1000 population. 28 A large systematic review and meta-analysis revealed the high incidence (15%) of DEP in the first year following AP, increasing further (23%) at 5 years. 41 Patients with other conditions commonly associated with DEP, such as CF, 42 hereditary hemochromatosis, and transfusion overload due to, for example, thalassemia major, 43 should also be screened for DEP. International guidelines recommend screening for CF-related diabetes (CFRD) from childhood; abnormalities in glucose tolerance may be present for many years prior to a definitive diagnosis of diabetes. Risk factors for DEP include more severe gene mutations, poor pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, a family history of T2DM, and corticosteroid use. 9, 44 The prevalence of diabetes associated with hemochromatosis is falling due to proactive secondary screening of family members; this results in earlier age of diagnosis and an opportunity for improved management to prevent complications. 45 However, as only 60-80% of those with a genetic risk develop biochemical penetrence and there is not always a family history, clinicians need to consider a diagnosis in individuals with diabetes and abnormal liver function tests, arthritis, or other endocrinopathies. 23 Screening for glucose intolerance and diabetes should be routine for all patients with thalassemia major. 43 The incidence of DEP in these patients ranges from under 5% up to 25% depending on the timing of screening, transfusion burden, intensity of chelation therapy, compliance factors, and the presence or absence of cirrhosis. Newer chelation regimens that combine desferoxamine and deferiprone are highly effective and can reverse glucose intolerance in this group. 46 In a small subset of patients, incident diabetes may herald an underlying pancreatic ductal adenocarcinoma. 47 When diabetes and pancreatic ductal adenocarcinoma coexist, the diabetes usually precedes the diagnosis of adenocacinoma by 24 months in 74-88% of patients. 17 UK guidelines recommend urgent imaging to assess for pancreatic cancer in people aged over 60 years with weight loss and new-onset diabetes. 18 
Diagnosis
The diagnosis of DEP is based upon standard criteria for diabetes mellitus: clinical symptoms of hyperglycemia and glucose of ≥ 11.1 mmol/L or in asymptomatic individuals with at least two abnormal biochemical tests: fasting glucose 7.0 mmol/L, 2-h glucose ≥ 11.1 mmol/L after 75-g oral glucose ingestion, or HbA1c ≥ 6.5% (48 mmol/mol). 1 The 75-g glucose tolerance test remains the gold standard for diagnosis of DEP. However, currently, there is no consensus as to whether all diabetes concurrent with pancreatic disease should be considered as DEP or if more stringent diagnostic standards should be used.
Ewald and Bretzel proposed the following diagnostic criteria: 48 • A diagnosis of diabetes mellitus • Evidence of exocrine pancreatic insufficiency (fecal elastase-1 < 200 μg/g or abnormal direct function testing) • Abnormal pancreatic imaging (endoscopic ultrasound, magnetic resonance imaging, and computed tomography) • Absence of type 1 diabetes associated autoimmune markers (antibodies against glutamine acid decarboxylase, islet cell antigen, or insulin)
These criteria are useful but have been criticized for the difficulty of applying them to all clinical settings. 49 Sensitivity may be compromised as reduced exocrine function has also been found in T1DM and T2DM. Conversely, specificity may be lower than expected as overt exocrine dysfunction may not be evident in pancreatic ductal adenocarcinoma. 31 The classification is further complicated by the high prevalence of T2DM that may overlap with DEP. 38 Characteristics of DEP include impaired β cell function; lack of insulin resistance; deficiency of lipid-soluble vitamins A, D, E, and K; and impaired release of GLP-1 and PP. Indeed, a reduced PP response to mixed nutrients (less than twice the basal level) has been identified as a specific marker. 31, 39 Evidence of pancreatic destruction, surgical removal of the pancreas, or recent onset of diabetes in a patient with adenocarcinoma provide pragmatic support for a diagnosis of DEP. 5 The onset of DEP is abrupt after pancreatectomy. DEP may develop gradually in other situations, potentially with a period of pre-diabetes, prior to diagnosis at screening or when overt symptoms develop.
Clinical presentation
The clinical presentation of DEP is distinct from that of T1DM and T2DM. Woodmansey et al. compared adult patients with newonset diabetes and a prior diagnosis of acute (n = 361) and chronic (n = 198) pancreatic disease to those without a diagnosis of pancreatic disease. 4 These criteria were wider than those used by Ewald and Bretzel 48 to define DEP. Patients with DEP were diagnosed at a median age of 59 years and had a BMI 29 kg/m 2 . These demographics were similar to the group with T2DM, perhaps explaining the difficulty in differentiating between the two conditions. Importantly, the group with diabetes after pancreatic disease was significantly more likely to require insulin (29.6%) compared with T2DM (4.1%) 5 years after diagnosis. Diabetes following pancreatic disease was associated with a 1.7 times increased likelihood of poor glycemic control (HbA1c ≥ 7% or 53 mmol/mol) at 5 years when compared with T2DM. 4 Patients with DEP should be under regular surveillance for diabetic complications. The microvascular complications of diabetes mellitus are a consequence of hyperglycemia and are reduced by achieving good glycemic control. 1 In patients with DEP, prolonged untreated hyperglycemia results in a similar incidence of microvascular disease as in T1DM. 31 Although the majority of CFRD patients have isolated post-prandial hyperglycemia, clinicians should be aware that those who develop fasting hyperglycemia are at risk of microvascular complications. 50 
Treatment strategies
Lifestyle and pharmacological therapy should be used to ensure adequate nutrition, bone health, and glycemic control. Dietary advice (individualized for nutritional status), exercise, alcohol use, and smoking cessation are vital to overall health outcomes.
Dietary interventions. The majority of patients with DEP due to CP have abnormal exocrine pancreatic function with an accompanying degree of fat malabsorption. 51 Medical management should focus on preventing malnutrition, supplementing fat-soluble vitamins if deficient, reducing symptoms of steatorrhea, and optimizing glycemic control. Screening for fat-soluble vitamins A, D, E, and K can help ensure nutritional deficiency and monitor the effectiveness of pancreatic enzyme replacement therapy (PERT). 51 PERT and vitamin D replacement are both important for nutrition and bone health. 52 Protein and fat malabsorption becomes clinically apparent when over 90% of exocrine function is lost. However, patients with subclinical deficiency may have an impaired incretin response contributing to postprandial hyperglycemia. PERT may improve the incretin response to a meal and has been found to improve glycemia in small studies of alcoholic pancreatitis 34 and CF. 53 One crossover study of five non-diabetic patients with CF demonstrated that PERT reduced peak post-prandial glucose level (8.2 vs 13.7 mmol/L) and restored GLP-1 secretion and gastric emptying following a mixed high-fat, high-carbohydrate meal. Further studies are needed to determine if PERT improves longer term glycemic control in DEP.
Metformin therapy. Metformin has been shown to reduce the risk of pancreatic ductal adenocarcinoma in a case-control study (odds ratio 0.38) 54 and in a meta-analysis of retrospective observational studies (relative risk 0.63) 55 of patients with T2DM. The anti-neoplastic effect of metformin may be due to activation of the liver kinase B-1-adenyl monophosphate protein kinase pathway, a known inhibitor of the mammalian target of rapamycin. 56 Metformin has been shown to reduce pancreatic ductal proliferation and prevent the development of adenocarcinoma in an animal model. Patients with CP have a high (5-10%) risk of pancreatic ductal adenocarcinoma over the course of 20 years. 31 Metformin should be considered as part of the treatment for patients with DEP due to CP; however, outcome studies for this group are not yet available.
Incretin therapy. Conversely, the use of medications that potentiate the incretin response, for example, injectable GLP-1 analogues and oral dipeptidyl peptidase-4 inhibitors, is controversial in patients with DEP due to their possible association with pancreatitis and pancreatic cancer. 38 It has been argued that this association may be mediated by the increased use of these drugs in obese individuals. 57 Although the incretin pathway is an appealing target in DEP, further safety studies are needed before these drugs can be recommended. In the interim, appropriate replacement with PERT provides a direct route by which to optimize the incretin response.
Insulin therapy. The majority of patients with DEP will require early insulin therapy. Patients should be counseled on the symptoms of decompensated hyperglycemia and the likely need for insulin treatment. Insulin may be needed transiently during episodes of AP, during which oral agents may be ineffective and potentially harmful. 38 Insulin therapy should be initiated with a dosing calculation similar to those used in T1DM, as many patients with DEP exhibit preserved peripheral insulin sensitivity and are prone to hypoglycemia. Higher doses may be needed in well-nourished patients with hemochromatosis and insulin resistance due to hepatic involvement. 45, 58 Cystic fibrosis patients with diabetes, particularly women, are at risk of poor nutrition, weight loss, deteriorating lung function, and reduced survival. 24 The life expectancy of people with CF has increased and insulin therapy for CFRD may have contributed to improved outcomes. Insulin has desirable anabolic effects, and there is some evidence of a reversal of bodyweight loss in CF patients with insulin-treated diabetes. 50 Recent data have suggested that oral repaglinide may provide equivalent outcomes to short-acting meal-time insulin in CF patients with newly diagnosed diabetes: After 2 years of treatment, glycemic control, body mass index, and lung function were similar in both groups. 59 Diabetes of the exocrine pancreas may present in up to 25% of patients as a severe form of "brittle diabetes" characterized by rapid fluctuations in glucose levels. 27, 48, 52 These patients are hypoglycemia-prone due to a combination of low glucagon secretion and intact peripheral insulin sensitivity; they are disposed to hyperglycemia as a result of insulin and PP insufficiency with consequent hepatic glucose production. This is challenging when planning insulin therapy and may contribute to the poor glycemic control observed in comparison with T2DM. 4 
Conclusion
Diabetes of the exocrine pancreas is a poorly recognized entity often misdiagnosed as T2DM.
3,4 DEP should be considered in patients with pre-existing disease of the pancreas or after pancreatic resection. AP and CP are common causes, but people with CF, hemochromatosis, and thalassemia major should be screened for DEP, and it should be considered in patients with ductal adenocarcinoma, trauma, ischemia, or surgery of the pancreas. Early recognition of DEP allows intervention before the development of critical insulin deficiency. A diagnosis of DEP provides an opportunity to provide PERT and select appropriate diabetes medications.
The obesity epidemic has led to an increasing prevalence of T2DM, which in clinical practice may overlap with DEP. Obesity leads to fatty infiltration of the pancreas 60, 61 and an (initially reversible) defect in insulin secretion. 62, 63 This contributes to the risk and severity of pancreatitis 61 and may be a risk factor for pancreatic adenocarcinoma, 61, 64 independent of obesity and diabetic status. 60 The relationship between "fatty pancreas," pancreatitis, pancreatic carcinoma, and DEP is likely multidirectional. Understanding the causality of these relationships is an important area for investigation. The potential benefits of interventions that reduce pancreatic fat warrant further exploration.
Clinical trials are needed to explore the most effective long-term management of DEP. Although the Diabetes Control and Complications Trial and UKPDS trials provide definitive evidence for intensive glycemic management in patients with T1DM and T2DM, both studies excluded patients with pancreatic disease. The development of a consensus diagnostic tool to distinguish DEP from other subtypes of diabetes would aid the clinician. Further research is needed to evaluate current treatments and to identify novel therapeutic targets for the management of DEP.
